A detailed history of Charles Schwab Investment Management Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 565,503 shares of PTGX stock, worth $22.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
565,503
Previous 525,653 7.58%
Holding current value
$22.2 Million
Previous $18.2 Million 39.53%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$33.72 - $47.33 $1.34 Million - $1.89 Million
39,850 Added 7.58%
565,503 $25.4 Million
Q2 2024

Aug 12, 2024

BUY
$24.66 - $34.8 $717,384 - $1.01 Million
29,091 Added 5.86%
525,653 $18.2 Million
Q1 2024

May 08, 2024

BUY
$21.79 - $32.15 $898,641 - $1.33 Million
41,241 Added 9.06%
496,562 $14.4 Million
Q4 2023

Feb 06, 2024

BUY
$14.05 - $23.44 $227,876 - $380,173
16,219 Added 3.69%
455,321 $10.4 Million
Q3 2023

Nov 08, 2023

BUY
$16.68 - $23.66 $325,126 - $461,180
19,492 Added 4.65%
439,102 $7.32 Million
Q2 2023

Aug 09, 2023

BUY
$18.02 - $29.36 $1.05 Million - $1.72 Million
58,452 Added 16.18%
419,610 $11.6 Million
Q1 2023

May 11, 2023

BUY
$10.78 - $25.38 $227,856 - $536,457
21,137 Added 6.22%
361,158 $8.31 Million
Q4 2022

Feb 13, 2023

BUY
$7.36 - $11.17 $46,942 - $71,242
6,378 Added 1.91%
340,021 $3.71 Million
Q3 2022

Nov 14, 2022

BUY
$7.86 - $11.71 $69,836 - $104,043
8,885 Added 2.74%
333,643 $2.81 Million
Q2 2022

Aug 15, 2022

SELL
$7.06 - $25.52 $3,537 - $12,785
-501 Reduced 0.15%
324,758 $2.57 Million
Q1 2022

May 13, 2022

BUY
$23.34 - $36.08 $188,587 - $291,526
8,080 Added 2.55%
325,259 $7.7 Million
Q4 2021

Feb 11, 2022

BUY
$17.63 - $37.1 $129,527 - $272,573
7,347 Added 2.37%
317,179 $10.8 Million
Q3 2021

Nov 16, 2021

BUY
$12.95 - $49.69 $368,479 - $1.41 Million
28,454 Added 10.11%
309,832 $5.49 Million
Q2 2021

Aug 16, 2021

BUY
$25.57 - $44.88 $506,055 - $888,220
19,791 Added 7.57%
281,378 $12.6 Million
Q1 2021

May 17, 2021

BUY
$19.02 - $31.15 $691,700 - $1.13 Million
36,367 Added 16.15%
261,587 $6.78 Million
Q4 2020

Feb 16, 2021

BUY
$18.49 - $25.13 $161,491 - $219,485
8,734 Added 4.03%
225,220 $4.54 Million
Q3 2020

Nov 13, 2020

BUY
$15.19 - $22.4 $2.42 Million - $3.57 Million
159,414 Added 279.32%
216,486 $4.23 Million
Q2 2020

Aug 14, 2020

BUY
$6.19 - $18.84 $81,509 - $248,085
13,168 Added 29.99%
57,072 $1.01 Million
Q1 2020

May 15, 2020

BUY
$5.4 - $9.22 $815 - $1,392
151 Added 0.35%
43,904 $310,000
Q4 2019

Feb 07, 2020

BUY
$4.69 - $13.45 $14,721 - $42,219
3,139 Added 7.73%
43,753 $309,000
Q3 2019

Nov 08, 2019

BUY
$9.41 - $16.56 $39,004 - $68,641
4,145 Added 11.37%
40,614 $488,000
Q2 2019

Aug 09, 2019

BUY
$8.98 - $12.96 $327,491 - $472,638
36,469 New
36,469 $442,000
Q2 2018

Aug 08, 2018

SELL
$5.99 - $9.1 $193,566 - $294,066
-32,315 Closed
0 $0
Q1 2018

May 07, 2018

BUY
$8.46 - $23.08 $110,106 - $300,386
13,015 Added 67.44%
32,315 $278,000
Q4 2017

Jan 17, 2018

BUY
$14.47 - $20.8 $88,267 - $126,880
6,100 Added 46.21%
19,300 $402,000
Q3 2017

Nov 13, 2017

BUY
$10.61 - $17.98 $140,052 - $237,336
13,200
13,200 $234,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.93B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.